Views & Analysis | Perspectives on pharma industry issues

Skip to main content

Sunday 25 October 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Oncology

CatalYm's Scott Clarke from ESMO 2026

On GDF-15 neutralisation and cachexia, with CatalYm

As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Breast cancer ribbon

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

12 Questions with Julia Jakl

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Views & Analysis

Life Sciences minister Lord Prior: EMA probably can't stay, but we can create something even better

Could the EMA really stay in London?

After the UK voted to leave Europe, its seems obvious that the European Medicines Agency will have to leave London - but GSK’s Andrew Witty and others hope it might stay.

Views & Analysis

PH HW_ban_800 1

Exclusive: Frontiers Health – Day two coverage

Frontiers Health is a two-day event focused on disruptive health; innovative technology, application of digital and new ideas which can, are and will transform the face

Views & Analysis

Close up view of young woman holding ginseng vitamins and minerals pills in hand with capsule bottle on table. High angle view

Pharma’s new ‘sensible pricing’ behind cancer drug approvals...

A string of 'yes' decisions from NICE on cancer drugs - but what has changed?

Load more results

Sales & Marketing

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

The dangers of social media for pharma

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Digital

A sponsored video interview with Axria's Jeff Kaminski

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital

Data analytics and batch release

Better analytics leads to fewer regulator questions

Stronger data analytics is cutting the number of questions regulators ask about intensified processes.

Market Access

Market Access

MDM concept of patient data

Sponsored

The pre-commercial case for connecting data before acquiring...

For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.

Market Access

Two pills in the middle of multiple £1 coins

UK’s next pricing and access scheme to last for 7 years

Operational review meeting minutes released by the DHSC reveal industry and government are planning to move to a 7-year agreement.

Editor's Picks

ESMO26: Tango sees 82% ORR with combo in pancreatic cancer

Roche offers $15bn for strategic-level deal with Hansoh

ESMO26: Moderna, MSD reveal cancer jab data early after leak

Clinical trial setup times fall sharply in UK

Despite US policy changes, drug prices stay stubbornly high

Newsletters and Deep Dive
digital magazine

Get Newsletters

Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox

Oncology

Oncology

CatalYm's Scott Clarke from ESMO 2026

On GDF-15 neutralisation and cachexia, with CatalYm

As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Breast cancer ribbon

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Patients

Patients

pharmaphorum podcast Episode 281 - Cecilia Caetano, Bayer

Sponsored

Menopause is an urgent global health issue: Bayer’s Cecilia ...

Patients

female HCP confers with female patient

From bedside to breakthroughs: Reimagining the human experie...

Patients should be involved in the programme design process from the beginning, as co-creators with full influence over the outcome.

Patients

Hispanic heritage

Breaking Bipolar I disorder stigma in the Hispanic community

For many Hispanic patients and families, that is where the gap between need and treatment can begin.

R&D

R&D

Wooden pawns on top of wooden block named BOARD

Changing Faces: Board of Director and Advisory Board hires, ...

September’s boardroom moves brought seasoned pharma executives, investors, and scientific leaders into new governance and advisory roles across the life sciences sector.

R&D

Digital box and pills, supply chain concept for pharma

From reactive to predictive: How data is redefining pharma l...

Pharmaceutical supply chains have more data at their fingertips than ever before. The challenge is turning that information into foresight.

R&D

Depressed woman looks out rain spattered window in city

Removing barriers in treatment-resistant depression

pharmaphorum speaks with Hans Eriksson, psychiatrist and CMO of FundaMental Pharma, about why treatment resistance remains such a challenge.

Editor's Picks

ESMO26: Tango sees 82% ORR with combo in pancreatic cancer

Roche offers $15bn for strategic-level deal with Hansoh

ESMO26: Moderna, MSD reveal cancer jab data early after leak

Clinical trial setup times fall sharply in UK

Despite US policy changes, drug prices stay stubbornly high

News

OptiTROP-Lung06 PFS Graph

ESMO26: Sac-TMT delivers the goods in PD-L1-negative NSCLC

Kelun and MSD's TROP2-directed ADC, sac-TMT, reduced the risk of disease progression or death by 51% when used first-line in PD-L1-negative NSCLC.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company